Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beyond A-Beta: New Approaches To Alzheimer’s

This article was originally published in Start Up

Executive Summary

The track record for anti-amyloid beta Alzheimer’s treatments has been dismal. If upcoming results from pivotal trials for bapineuzumab and solanezumab are disappointing, they won’t scuttle the approach completely, but much more attention would shift toward other targets. We highlight two targets that have gained more attention of late, extracellular tau and ApoE4, and a diverse group of scientists working to move their work forward.


Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts